 Methods Study design and setting The study was a prospective randomized controlled trial that will recruit a maximal of 360 patients in eight tertiary Chinese hospitals over 2 years. All patients with new diagnosed ABAD in the participating hospitals will be screened for potential eligibility. The study was approved by the ethics committee of the hospitals 20160920-9. Written informed consents will be signed by the patients or their legally authorized representatives. The study was registered in the website of ClinicalTrial.gov . 